Mylan, Pfizer get federal OK for merger with Upjohn

Mylan and Pfizer said they have actually gotten approval from the Federal Trade Commission for their deal to combine Mylan with Pfizers off-patent drug organization, Upjohn..

In March, the companies said they d push back the merger until the second half of this year due to unanticipated hold-ups in getting regulatory approval triggered by the COVID-19 pandemic..

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this material? View our policies by click on this link.

Mylan and Pfizer first announced their strategies for a merger in July 2019 and stated the new business would be a worldwide pharmaceutical huge producing both generic and brand-name drugs. They said the brand-new company will offer widely known branded drugs such as Mylan EpiPen and Pfizers Viagra and could produce as much as $20 billion each year..

The new combined organization will be called Viatris, and its launching is anticipated to be Nov. 16.

More articles on pharmacy: Ascension launches drug store services service Ascension RxVirginia pharmacist gets 2 years in jail for prescription drug schemeAstraZeneca, Pfizer start accelerated evaluation for COVID-19 vaccines in UK.

Maia Anderson –
Tuesday, November 3rd, 2020
Print|Email.